Compare Eli Lilly And Co (LLY) vs Micron Technology, Inc. (MU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Micron Technology, Inc. — how do they compare? Eli Lilly And Co trades at $1,179.27 (market cap $1.04T), while Micron Technology, Inc. trades at $1,029 (market cap $1.17T). The key difference: Eli Lilly And Co and Micron Technology, Inc. are close in size by market cap, and Eli Lilly And Co pays the higher dividend (0.59%). Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and Micron Technology, Inc. for 48 Days on average.
| LLY | MU | |
|---|---|---|
Market Cap | $1.04T | $1.17T |
Volume | 3,064,878 | 29,425,906 |
Sector | Health | Technology |
52-Week High | $1.28K | $1.21K |
52-Week Low | $799.57 | $181.60 |
Typical Hold Time | 93 Days | 48 Days |
Enterprise Value | $1.09T | $1.13T |
Dividend Yield | 0.59% | 0.06% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,169.93, down 1.58% on the day, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The company demonstrates exceptional profitability with 83.4% gross margins and 33.53% net income margins, supported by dominant positioning in weight-loss and diabetes treatments. Recent clinical trial successes for next-generation drugs and expanded FDA approvals reinforce growth prospects.
LLY presents compelling growth potential with analyst consensus target of $1,350 representing 15% upside, though elevated valuations (P/E 39.26) and increasing competition in obesity drugs pose risks. Strong institutional support (73% buy ratings) and positive pipeline developments support continued momentum, but investors should monitor execution risks and market saturation concerns.
Micron Technology (MU) trades at $1,035.84, down 4.79% on the day but maintains strong technical momentum with a bullish moving average signal. The company demonstrates exceptional fundamental strength with 63.8% net income margin and 91.77% ROE, supported by three consecutive quarterly earnings beats. Recent strategic customer agreements covering 35% of revenue through 2030 provide visibility into sustained AI-driven memory demand growth.
Outlook remains positive with analyst consensus target of $1,590 representing 53% upside potential. Key opportunities include AI memory market expansion and supply constraints through 2028, while risks center on cyclical industry dynamics and potential growth deceleration. The stock's current valuation at 13.94 P/E appears reasonable given growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Micron Technology, Inc.
Micron historically focused on designing and manufacturing DRAM for PCs. The firm then expanded into the NAND flash memory market. It increased its DRAM scale with the purchase of Elpida (completed in mid-2013) and Inotera (completed in December 2016). The firm's DRAM and NAND products tailored to PCs, data centers, smartphones, game consoles, automotives, and other computing devices.
Read more on MU →
